HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor

Lancet

Volumn 352, Issue 9123, 1998, Pages 199-200

  Lisziewicz, Julianna ^b   Jessen, Heiko ^b   Finzi, Diana ^b   Siliciano, Robert F ^b   Lori, Franco ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HYDROXYUREA; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROLITHIASIS; PRIORITY JOURNAL;

EID: 0032543873     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)24029-3     Document Type: Article

References (5)

1. 1 Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science. 1994; 266: 801-05.
2. 2 Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. Granulecyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989; 169 (2): 933-51.
3. 3 Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls HIV-1 resistance. AIDS Res Hum Retroviruses 1997; 13: 1403-09.
4. 4 Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 287: 1295-300.
5. 5 Vila J, Nugier F, Bargues G, et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997; 250: 635-36